Publication:
SEOM-TTCC clinical guideline in nasopharynx cancer (2021).

Simple item page
dc.contributor.authorRueda-Dominguez, Antonio
dc.contributor.authorCirauqui, Beatriz
dc.contributor.authorGarcia-Castaño, Almudena
dc.contributor.authorAlvarez-Cabellos, Ruth
dc.contributor.authorCarral-Maseda, Alberto
dc.contributor.authorCastelo-Fernandez, Beatriz
dc.contributor.authorIglesias-Rey, Leticia
dc.contributor.authorRubio-Casadevall, Jordi
dc.contributor.authorArrazubi, Virginia
dc.contributor.authorMesia, Ricard
dc.date.accessioned2023-05-03T13:59:10Z
dc.date.available2023-05-03T13:59:10Z
dc.date.issued2022-03-18
dc.description.abstractNasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy (RT) is the cornerstone of locoregional treatment of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time.
dc.description.versionSi
dc.identifier.citationRueda Domínguez A, Cirauqui B, García Castaño A, Alvarez Cabellos R, Carral Maseda A, Castelo Fernández B, et al. SEOM-TTCC clinical guideline in nasopharynx cancer (2021). Clin Transl Oncol. 2022 Apr;24(4):670-680
dc.identifier.doi10.1007/s12094-022-02814-x
dc.identifier.essn1699-3055
dc.identifier.pmcPMC8986714
dc.identifier.pmid35303267
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986714/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s12094-022-02814-x.pdf
dc.identifier.urihttp://hdl.handle.net/10668/21108
dc.issue.number4
dc.journal.titleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
dc.journal.titleabbreviationClin Transl Oncol
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.page.number670-680
dc.provenanceRealizada la curación de contenido 12/05/2025
dc.publisherSpringer
dc.pubmedtypeJournal Article
dc.relation.publisherversionhttps://dx.doi.org/10.1007/s12094-022-02814-x
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectClinical Practice Guidelines
dc.subjectDiagnosis
dc.subjectFollow-up
dc.subjectNasopharyngeal cancer
dc.subjectTreatment
dc.subject.decsQuimioterapia
dc.subject.decsGemcitabina
dc.subject.decsCarcinoma Nasofaríngeo
dc.subject.decsEpidemiología
dc.subject.decsRadioterapia
dc.subject.decsHistología
dc.subject.meshHumans
dc.subject.meshNasopharyngeal Carcinoma
dc.subject.meshNasopharyngeal Neoplasms
dc.titleSEOM-TTCC clinical guideline in nasopharynx cancer (2021).
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number24
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC8986714.pdf
Size:
593.11 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Regional Universitario de Málaga
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
SAS - Hospital Universitario Virgen de la Victoria

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía